Efficacy and Safety of Novel Oral Anticoagulants in Elderly Patients with Non-Valvular Atrial Fibrillation: A Retrospective Cohort Study.
Adults aged 80 years or older with nonvalvular atrial fibrillation (NVAF) often have competing thromboembolic and bleeding risks, renal impairment, frailty, and dose-selection challenges. This single-center retrospective observational cohort included 202 adults aged 80 years or older who received warfarin (n = 56), edo...